Pfizer - AI Stock Analysis

Analysis generated February 9, 2026

Pfizer Inc. (NYSE: PFE) is a well-established pharmaceutical giant, founded in 1849 and headquartered in New York City. The company is primarily known for its wide portfolio of medicines, including vaccines and consumer healthcare products. Pfizer’s recent claim to fame is its COVID-19 vaccine, developed in collaboration with BioNTech. The company operates globally, generating billions in revenue, and is known for its commitment to innovation and substantial investments in R&D.

Fundamental Analysis

The financial numbers present a mixed picture for Pfizer. The revenue for the last quarter stood at $17.6 billion. This represents an increase of 5.42% compared to the previous quarter, which is a positive sign of growth. However, compared to the same quarter last year, there is a slight decrease of 1.16%, which could be a cause for concern and indicates the challenges faced in sustaining year-over-year growth.

Pfizer's net income for the last quarter was $1.65 billion. This value indicates a stark decrease of 146.54% compared to the previous quarter and a significant decrease of 508.93% compared to the same quarter last year. These negative percentages suggest pressing issues in cost management or other financial headwinds.

The EBITDA for the last quarter was $930 million, representing a decrease of 116.47% compared to the previous quarter and 118.08% year-over-year. This downturn is alarming, as EBITDA is crucial for assessing operational profitability. The current P/E ratio stands at 20.01, which is within a normal range, suggesting that the stock is neither undervalued nor overvalued according to traditional metrics.

Technical Analysis

The current stock price of Pfizer is $27.05. This price showcases an increase of 7.94% compared to a month ago, indicating a positive short-term trend. On a longer horizon, there is an increase of 12.19% compared to a year ago, reinforcing a bullish sentiment. The trend is indeed bullish.

The 10-day Simple Moving Average (SMA10) is 26.73 compared to the previous SMA10 of 26.67, indicating a potential upward trend in price movement. However, the Relative Strength Index (RSI) is at 71.6, which suggests an overbought condition and potential bearish sentiments creeping in.

Alternative Data Analysis

Considering alternative data, Pfizer has 696 open positions, up by 18% in the last couple of months. This indicates that the company is looking to expand, which can be seen as a positive growth signal.

The business outlook among Pfizer employees is neutral according to various employee sentiment analyses. In customer acquisition and engagement areas, Pfizer’s website attracts an estimated 2.4 million visitors per month, with no significant changes recently. On social media, the company maintains 120,000 followers on Instagram and 470,000 followers on Twitter. The latter metric has seen a 1% decrease in recent months, indicating a slight loss in customer interest.

Lastly, Pfizer's AI score from AltIndex is 55, which suggests a hold signal, reflecting a balanced outlook when considering fundamental, technical, and alternative data.

Conclusion

In summary, Pfizer’s stock shows a mixed financial picture with improved quarterly revenue but drastic declines in net income and EBITDA. The technical indicators imply a short-term bullish trend, although the high RSI calls for caution. Alternative data reflects expansion efforts by Pfizer but also suggests neutral employee sentiment and stable customer engagement. Considering all the data provided, the overall recommendation would be to hold Pfizer’s stock, acknowledging both growth opportunities and potential risks.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.